Virological failure and drug resistance during first line anti‐retroviral treatment in Indonesia

Abstract

The virological response and development of drug resistance during first-line anti-retroviral treatment (ART) were studied in Indonesia where the majority of patients infected with HIV have a history of injecting drug use, which is often linked with lower treatment adherence and development of drug-resistance. As many as 575 patients starting ART between September 2007 and March 2010 in Hasan Sadikin Hospital Bandung were followed prospectively. Clinical and laboratory monitoring was performed every 6 months. Plasma samples with HIV-RNA ≥ 400 copies/ml were examined for drug resistance mutations. Most patients were male (72.3%), 59.7% had a history of injecting drug use, and the median CD4+ cells count before start of ART was 35 cells/mm(3) (IQR 10-104). From 438 HIV patients with HIV-RNA measurements, 40 (9.1%) subjects had HIV-RNA ≥ 400 copies/ml after 24 weeks (median follow-up 16 (IQR 8-25) months). Of these failing patients 16 (47%) subjects had drug resistance mutations, predominantly M184V (35.3%), Y181C (23.5%), K103N (11.7%), and TAMs (11.7%). A history of treatment discontinuation ≥ 1 month, reported by 5.3% (23) of patients, was strongly associated with virological failure (adjusted OR 12.64, 95% CI 4.51-35.41); and a history of injecting drug use was not (OR 0.75, 95% CI 0.38-1.46). This is the largest and most systematic evaluation of virological response to first line ART in Indonesia. Patients in this cohort responded well to first line ART, with low rates of virological failure and drug resistance. A history of injecting drug use should not be a reason to withhold ART in this setting.

Pattern of HIV-1 Drug Resistance among Adults on ART in Nigeria

“…The finding that 50% and 100% of those on 1 st line and 2 nd line drugs respectively had major drug resistance mutations compared to 4.8% of ART naïve indicates that these mutations developed as a result of ART use rather than transmission of resistant strains. Drug pressure as well as poor drug adherence and drug absorption rate that lead to circulation of sub-optimal blood level of drug are known factors that contribute to the development of drug resistance mutations [22,40,42,43].…”

Bioinformatics and Regression Analyses Manifest Tumor-Specific miRNA Expression Dynamics in Pediatric Embryonal Malignancies

“…In brief, the patient cohort included 8 males and 11 females, with minimum age of 0.03 years to maximum 10.2 years (mean age 5.65 years). The median age of MB patients was 7.5 years with a male/female ratio of 1:1.The median age for the AT/RT patients was 1.1 years with a male/female ratio 1 http://bioinformatics.psb.ugent.be/webtools/Venn/ of 1:3, and the median age of the non-malignant cohort was 9 years with a male/female ratio of 1:0.…”

“…Central nervous system (CNS) neoplasms of childhood of embryonal origin comprise of a group of malignant neoplasms that are by far the largest group of malignant brain tumors in childhood, highly associated with increased mortality and long-term morbidity. All embryonal neoplasms are staged as grade IV malignancies and they consist of medulloblastomas (MBs) and atypical teratoid/rhabdoid tumors (AT/RTs), among others [1].…”

Microrna expression signatures predict patient progression and disease outcome in pediatric embryonal central nervous system neoplasms

“…All embryonal tumors are classified pathologically as grade IV malignancies and they are largely comprised of medulloblastomas (MBs) and atypical teratoid/rhabdoid tumors (AT/RTs), among others [1]. Medulloblastoma is considered the most common malignant pediatric brain tumor, accounting for 20% of cases [2].…”